Wolfe Research Downgrades Centessa Pharmaceuticals to Peer Perform

Wolfe Research analyst Rudy Li has downgraded Centessa Pharmaceuticals (NASDAQ: CNTA) from an Outperform rating to a Peer Perform rating. This change reflects a shift in the analyst's outlook on the company's performance relative to its peers.